Split-Dose Radiation After Surgery Cuts Brain Tumor Recurrence in Landmark Trial

For the hundreds of thousands of patients whose cancer spreads to the brain each year, one of the most stubborn clinical challenges has long been what to do after a surgeon removes a large metastatic tumor. Microscopic cancer cells inevitably linger around the edges of the surgical cavity, and if they are not destroyed, the tumor frequently grows back exactly where it was taken out. Now, results from a randomized phase III trial conducted by the Alliance for Clinical Trials in Oncology suggest that the answer lies not in a bigger dose, but in a smarter schedule: delivering focused radiation in three to five separate sessions rather than a single blast dramatically improves control of the disease at the surgical site and, remarkably, appears to extend survival. The findings were presented at the plenary session of the American Society for Radiation Oncology annual meeting in Boston, a slot reserved for studies with the potential to change clinical practice worldwide.

The trial, known as Alliance A071801, enrolled 242 patients at multiple centers across the United States between 2019 and 2022. Each participant had between one and four brain metastases, including at least one lesion larger than two centimeters that had been surgically removed. Patients were randomly assigned to receive either single-session radiosurgery or fractionated stereotactic radiosurgery delivered over three or five sessions, with radiation doses calibrated to the size of the treatment area. Any metastases that had not been removed surgically were treated according to the same schedule assigned to the patient. Researchers then followed the participants for a median of four years, tracking whether cancer returned at the operative site, whether other brain tumors progressed, how long patients lived, and what side effects emerged.

The results were striking. One year after treatment, 87 percent of patients who received the multi-session approach remained free from recurrence at the surgical site, compared with 81 percent of those who received a single session, a difference that reached statistical significance. In the world of postoperative brain radiation, where recurrence rates have historically been discouragingly high, a six-percentage-point improvement in local control represents a meaningful advance. The trial also hinted at broader benefits: among unresected tumors that were treated with radiation, progression occurred later in only 4 percent of patients in the fractionated group versus 11 percent in the single-session group, although that difference did not reach statistical significance.

Even more unexpected was the survival signal. Patients treated with fractionated radiosurgery lived a median of 29 months, compared with 20 months for those treated in a single session, a nine-month difference that would be considered substantial in almost any cancer setting. Fractionated treatment was associated with a 31 percent lower risk of death, and that association remained significant even after researchers adjusted for patient and treatment characteristics. Importantly, rates of adverse events were low in both arms and did not differ significantly between the groups, meaning the multi-session approach achieved its benefits without adding toxicity.

Paul D. Brown, MD, the trial’s principal investigator and the Wilmeth Professor of Radiation Oncology at Mayo Clinic in Rochester, Minnesota, explained the biological logic behind the approach. After surgery for a large brain metastasis, the challenge is delivering enough radiation to eliminate microscopic cancer cells left behind without exposing too much healthy brain to a high single dose, he noted. Dividing the radiation over several treatments gives healthy tissue time to recover between doses while still delivering an effective dose to the treatment area. By fractionating the treatment, the research team was able to improve local control while maintaining a similar safety profile. The principle at work is a cornerstone of radiation biology: normal brain tissue tolerates the same total dose better when it is delivered in smaller increments, because sublethal DNA damage in healthy cells can be repaired between sessions, while tumor cells are less efficient at such repair.

The significance of the finding becomes clearer in the context of how brain metastases have been managed. Brain metastases occur when cancer that began elsewhere in the body, most commonly the lung, breast, skin, or kidney, spreads to the brain. An estimated 200,000 people in the United States develop them each year, and incidence is rising as advances in systemic cancer treatment extend survival for many patients, creating a growing population at risk of developing these lesions. Large metastases may require surgery when they press on the brain or cause symptoms such as seizures, headaches, or difficulty speaking or moving. Radiation therapy after surgery is standard because microscopic disease around the cavity is common; in a previous randomized trial, more than half of patients who had surgery without postoperative radiation experienced recurrence at the surgical site within a year.

For patients with a limited number of resected brain metastases, current guidelines recommend treating the surgical cavity with stereotactic radiosurgery, a technique that delivers highly focused beams precisely shaped to the target, rather than whole-brain radiation therapy, which can impair memory and cognitive function and diminish quality of life. But the optimal way to deliver postoperative radiosurgery for larger cavities had never been definitively established. With larger treatment areas, the dose that can be safely given in a single session is limited by the volume of surrounding healthy brain exposed to radiation. Retrospective studies had suggested that dividing the dose across several sessions might safely improve local control, but those observations were subject to selection bias and had never been tested in a randomized phase III trial until now.

Ayal A. Aizer, MD, a study co-author and radiation oncologist at Dana-Farber Brigham Cancer Center in Boston, emphasized how the evidence base has changed. This study moves fractionated radiosurgery from a reasonable practice supported by retrospective data to one backed by a randomized phase III trial, he said. For patients with larger brain metastases, three to five sessions should now be considered a standard postoperative treatment. That statement carries practical weight: fractionated radiosurgery requires patients to return to the clinic on multiple days, and some centers have hesitated to adopt the schedule without firm evidence. The trial results could help standardize a practice that some radiation oncologists have already embraced based on weaker data, reducing variation in care and giving patients and physicians a clearer basis for treatment decisions.

The survival difference, however, remains a puzzle that the investigators themselves are careful not to overinterpret. The study was not designed to determine why patients in the fractionated arm lived longer, and the treatment groups were well balanced on measured characteristics at the start of the study. Additional analyses did not identify a clear explanation for the difference, and the researchers cautioned that more research is needed before drawing firm conclusions. Brown said the team was pleased to see better control at the surgical site because that finding aligns closely with the retrospective evidence that motivated the trial, but the survival difference was surprising and cannot yet be explained with certainty. One plausible hypothesis, which the researchers themselves did not confirm, is that as modern systemic therapies help patients live longer with cancer, maintaining durable control of disease in the brain may play an increasingly important role in long-term outcomes, allowing patients to benefit more fully from the treatments that control their disease elsewhere.

What the trial does establish with confidence is a new benchmark for postoperative care of large brain metastases. The findings provide the strongest evidence to date supporting fractionated radiosurgery after surgery for larger lesions, and they arrive at a moment when the population of patients living with brain metastases is expanding. For a disease that once carried a uniformly grim prognosis, the ability to keep the brain free of tumor for longer, using a treatment schedule that patients already tolerate well, represents exactly the kind of practice-changing result that phase III trials are designed to deliver. As the data move from conference presentation toward peer-reviewed publication and guideline revision, patients facing surgery for a large brain metastasis can expect a conversation that increasingly begins not with whether to receive postoperative radiosurgery, but with how many sessions it should take to keep their cancer from coming back.

Subject of Research: Fractionated versus single-session stereotactic radiosurgery after surgery for large brain metastases

Article Title: Alliance trial finds fractionated radiosurgery reduces cancer recurrence after surgery for large brain metastases

Article References: Alliance trial finds fractionated radiosurgery reduces cancer recurrence after surgery for large brain metastases. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: brain metastases, stereotactic radiosurgery, fractionated radiation, Alliance A071801, clinical trial, ASTRO, radiation oncology, local control, overall survival, surgical cavity, cancer recurrence, Mayo Clinic